Skip to main content

Table 1 Mitophagy inhibitors and inducers in anticancer therapeutics

From: Mitophagy in carcinogenesis, drug resistance and anticancer therapeutics

No Drug Mitophagy inhibitor or inducer Mechanisms in anticancer therapeutics
1 Melatonin Inhibitor Downregulates c-Jun N-terminal kinase (JNK) and subsequently Parkin, and aggravates cell apoptosis [85]
2 Mdivi-1 Inhibitor Increases the susceptibility of hepatic cancer cells to cisplatin by increasing mitochondrial membrane permeability [86]
3 Liensinine Inhibitor Suppresses the excessive accumulation of autophagosomes, autophagosome-lysosome fusion and the maturation of several important lysosomal hydrolases [87]
4 Ketoconazole Inducer Induces PINK1-Parkin mitophagy pathway by downregulating the expression of COX-2 and promotes the apoptosis of hepatic carcinoma cells [88]
5 Sorafenib Inducer Stabilizes PINK1 on the outer membrane of mitochondria and recruits Parkin to dysfunctional mitochondria to initiate mitophagy in liver cancer cells [89]
6 Mito-CP and Mito-Metformin Inducer Release ULK1 from mTOR-mediated inhibition, decrease mitochondrial membrane potential, and abrogate colorectal cancer cell proliferation [90]